Our concerns about making the "early" July TDAPA deadline are probably overblown. Here's why..."Frequency of Early Approval: An analysis of novel drug approvals between 2013 and 2022 showed that 98% of drugs met or exceeded PDUFA goal dates, with many approvals occurring ahead of that date".
That explains why the company is confident they'll make the TDAPA cutoff.
Yes we have an ATM!
I think the need to raise money is not a major worry either. "Unicycive Therapeutics, Inc. has amended its existing at-the-market equity program with Guggenheim Securities to expand potential common stock sales. The company previously could sell shares of common stock with an aggregate offering price of up to $50,000,000 under its Form S-3 shelf registration. As of November 14, 2025, Amendment No. 1 to the Sales Agreement increases the maximum aggregate offering price that may be sold in the ATM offering to $100,000,000. The ATM offering allows the company to issue and sell shares from time to time".
I think the sell off is an over reaction, JMO.
Market Data 
Markets 
AI
